Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | EDNRA | P25101 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 5/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.51 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.51 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL326633 | 0.84 | ALDH1A1 (0.71) | ALDH1A1LMNAKDM4ECYP2C9EDNRA | |
| Hydrochloric Acid SCHEMBL27575105 | 0.83 | ALDH1A1 (0.69) | ALDH1A1LMNAKDM4ECYP2C9EDNRA | |
| SCHEMBL3070565 | 0.79 | ALDH1A1 (0.68) | ALDH1A1LMNAKDM4ECYP2C9EDNRA | |
| SCHEMBL15116297 | 0.78 | ALDH1A1 (0.81) | ALDH1A1LMNAKDM4ETDP1KMT2A | |
| SCHEMBL1094563 | 0.78 | SCN9A (0.55) | KMT2AGLO1SLC40A1 | |
| SCHEMBL712101 | 0.78 | ALDH1A1 (0.71) | ALDH1A1LMNAKDM4ECYP2C9EDNRA | |
| SCHEMBL12383540 | 0.78 | ALDH1A1 (0.62) | ALDH1A1LMNAKDM4ECYP2C9EDNRA | |
| SCHEMBL713015 | 0.78 | LMNA (0.71) | ALDH1A1LMNAKDM4ECYP2C9EDNRA | |
| SCHEMBL6312978 | 0.77 | ALDH1A1 (0.57) | ALDH1A1LMNAKDM4ECYP2C9EDNRA | |
| SCHEMBL19613863 | 0.77 | LMNA (0.69) | ALDH1A1LMNAKDM4ECYP2C9EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8907101-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-20130338111-A1 | Sulfonamide Derivatives | ICAGEN, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-20120149679-A1 | Sulfonamide Derivatives | ICAGEN, INC. | 2012-06-14 | — | — | US | disclosed |
| CN-101842372-A | Pyridyl sulfonamides as modulators of ion channels | VERTEX PHARMA | 2010-09-22 | — | — | CN | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, TPST2 | ALDH1A1 1369/4885LMNA 2523/4885KDM4E 4039/4885 |
| US-20130338111-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | ALDH1A1 1369/4885LMNA 2523/4885KDM4E 4039/4885 |
| US-20120149679-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | ALDH1A1 1369/4885LMNA 2523/4885KDM4E 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.